Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-label Extension Study of Casimersen or Golodirsen in Duchenne Muscular Dystrophy
2017-004625-32Phase 3Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jul 2018
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of casimersen and golodirsen in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Sarepta Therapeutics. Primary endpoint: Patient incidence of serious adverse events (SAEs). Started Jul 2018; status: completed.
02
Drugs
casimersengolodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2017-004625-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004625-32.